Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-09-14 18:00 |
Biophytis annonce l’émission d’une tranche d’ORNANE d’un montant de 3 millions …
|
French | 184.3 KB | ||
| 2020-09-14 18:00 |
Biophytis announces the issuance of a €3 million tranche of ORNANE
|
English | 215.8 KB | ||
| 2020-09-01 08:00 |
Biophytis Enrolls First Patient in COVA, a Multinational Phase 2/3 Clinical Tri…
|
English | 190.9 KB | ||
| 2020-09-01 08:00 |
Biophytis : Inclusion du premier patient dans COVA, un essai clinique internati…
|
French | 171.0 KB | ||
| 2020-08-28 19:00 |
Biophytis fait le point sur l’état d’avancement de SARA-INT, un essai clinique …
|
French | 180.9 KB | ||
| 2020-08-28 19:00 |
Biophytis provides an update on SARA-INT, a Phase 2b clinical trial evaluating …
|
English | 181.5 KB | ||
| 2020-08-04 08:00 |
Biophytis obtient l’autorisation de l'agence brésilienne de réglementation de l…
|
French | 160.6 KB | ||
| 2020-08-04 08:00 |
Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start CO…
|
English | 183.5 KB | ||
| 2020-07-27 08:00 |
Biophytis obtient l’autorisation de l’ANSM de démarrer l’essai clinique COVA av…
|
French | 171.6 KB | ||
| 2020-07-27 08:00 |
Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate…
|
English | 211.8 KB | ||
| 2020-07-03 08:00 |
Biophytis annonce un financement par placement privé de 6,1 millions d’euros
|
French | 209.9 KB | ||
| 2020-07-03 08:00 |
Biophytis announces a € 6.1 million capital increase through private placement
|
English | 207.7 KB | ||
| 2020-07-01 21:05 |
Biophytis reçoit l’accord de la FDA pour démarrer l’essai clinique COVA de phas…
|
French | 161.7 KB | ||
| 2020-07-01 21:05 |
Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with …
|
English | 182.5 KB | ||
| 2020-07-01 21:00 |
Biophytis annonce l’émission d’une tranche d’ORNANE d’un montant de 3 millions …
|
French | 187.6 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
